Yahoo
NasdaqCM - Delayed Quote USD

Avalo Therapeutics, Inc. (AVTX)

19.23 +0.23 (+1.21%)
At close: 4:00:01 PM EDT
19.23 0.00 (0.00%)
After hours: 4:34:51 PM EDT
Trade AVTX on Coinbase
Chart Range Bar
Loading chart for AVTX
  • Previous Close 19.00
  • Open 18.81
  • Bid 13.32 x 200
  • Ask 24.21 x 200
  • Day's Range 18.80 - 19.58
  • 52 Week Range 9.54 - 24.27
  • Volume 633,217
  • Avg. Volume 1,250,184
  • Market Cap (intraday) 1.031B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -4.41
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 44.15

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

www.avalotx.com

33

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AVTX
5.89%
S&P 500 (^GSPC)
12.75%

1-Year Return

AVTX
89.27%
S&P 500 (^GSPC)
18.71%

3-Year Return

AVTX
11.95%
S&P 500 (^GSPC)
70.93%

5-Year Return

AVTX
99.78%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -36.36M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-30M
-20M
-10M
0
-20000.0%
-15000.0%
-10000.0%
-5000.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

30.00
44.15 Average
19.23 Current
60.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 50 -> 48

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    1.04B

  • Enterprise Value

    616.79M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.72k

  • Price/Book (mrq)

    2.40

  • Enterprise Value/Revenue

    10.45k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -18.50%

  • Return on Equity (ttm)

    -36.27%

  • Revenue (ttm)

    59k

  • Net Income Avi to Common (ttm)

    -100.33M

  • Diluted EPS (ttm)

    -4.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    400.28M

  • Total Debt/Equity (mrq)

    0.05%

  • Levered Free Cash Flow (ttm)

    -23.27M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

19.23 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: